Last update 23 Jan 2025

ART-001(Accuredit)

Overview

Basic Info

Drug Type
Gene editing
Synonyms
Target
TTR
Mechanism
TTR modulators(Transthyretin modulators)
Therapeutic Areas
Nervous System DiseasesCardiovascular DiseasesEndocrinology and Metabolic Disease+ [1]
Active Indication
Amyloid NeuropathiesTransthyretin Amyloid CardiomyopathyTransthyretin cardiac amyloidosis+ [1]
Inactive Indication-
Originator Organization
Accuredit Therapeutics (Suzhou) Co., Ltd.
Active Organization
Accuredit Therapeutics (Suzhou) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with ART-001(Accuredit)
CTR20243298
/ Not yet recruitingPhase 1/2
ART001注射液治疗转甲状腺素蛋白淀粉样变性心肌病的多中心、开放、单臂I/IIa期临床研究
[Translation] A multicenter, open, single-arm phase I/IIa clinical study of ART001 injection in the treatment of transthyretin amyloid cardiomyopathy
CTR20243089
/ Not yet recruitingPhase 1/2
ART001注射液治疗转甲状腺素蛋白淀粉样变性多发性神经病的多中心、开放、单臂I/IIa期临床研究
[Translation] A multicenter, open, single-arm phase I/IIa clinical study of ART001 injection in the treatment of transthyretin amyloid polyneuropathy
ChiCTR2400081216
/ RecruitingEarly Phase 1
(Open-Label, Single Ascending Dose) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ART001 in Patients with Transthyretin Amyloidosis
100 Clinical Results associated with ART-001(Accuredit)
Login to view more data
100 Translational Medicine associated with ART-001(Accuredit)
Login to view more data
100 Patents (Medical) associated with ART-001(Accuredit)
Login to view more data
100 Deals associated with ART-001(Accuredit)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Amyloid NeuropathiesPhase 2
CN
Accuredit Therapeutics (Suzhou) Co., Ltd.
30 Aug 2024
Transthyretin Amyloid CardiomyopathyPhase 2
CN
Accuredit Therapeutics (Suzhou) Co., Ltd.
30 Aug 2024
Transthyretin cardiac amyloidosisPhase 1
CN
Accuredit Therapeutics (Suzhou) Co., Ltd.
20 Oct 2023
Transthyretin-mediated amyloidosisIND Approval
CN
Accuredit Therapeutics (Suzhou) Co., Ltd.
22 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ChiCTR2400081216 (NEWS)
ManualManual
Early Phase 1
Amyloidosis, Hereditary, Transthyretin-Related
10
xflziapggz(dnrstvgqva) = 给药后4周，高剂量组受试者外周TTR蛋白较基线即可平均下降90%以上。 ieyeiirqsa (xaxcxnnufp )
View more
Positive
27 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free